Biosulin R instructions for use
Biosulin P is a medicinal product, which is an analog of human endogenous insulin of short action. This insulin is obtained by genetic engineering, as a result of which, according to the classification, Biosulin P belongs to the group of human genetically engineered insulins.
The onset of action occurs after 30-60 minutes and is observed for 6-8 hours.
Insulin receptors are found throughout the body, because it participates in virtually all metabolic processes and triggers a huge number of intracellular reactions. But the main organs for insulin are the liver, muscles and fatty tissue. Biological effects of insulin:
- regulation of carbohydrate metabolism as a result of increased transport and utilization of glucose by cells, thereby forming liver glycogen;
- suppression of the internal synthesis of glucose due to suppression of the cleavage of liver glycogen and reduction of glucose production from other sources;
- participation in the metabolism of fats, manifested by a decrease in their fats, which leads to a decrease in the ingress of free fatty acids into the blood;
- blocking the formation of ketones;
- the increase in production of fatty acids with their subsequent esterification, due to which an important coenzyme is formed in the body;
- participation in protein metabolism, which consists in increasing the transport of amino acids into cells, stimulating the production of peptides, reducing the consumption of proteins by tissues, inhibiting the formation of keto acids from amino acids.
- activation or inhibition of various types of enzymes.
Insulins are the main means of substitution therapy in the treatment of diabetes mellitus. The choice of the drug depends on the severity and features of the course of the disease, the patient's condition and the speed and duration of the hypoglycemic effect. Treatment is carried out according to individual schemes, for which insulin preparations of different duration of action are combined.
The dietary regime when using insulin should be limited by the energy value of food from 1700 to 3000 kcal.
When choosing the dosage, the blood sugar and urine are measured on an empty stomach and throughout the day. The final determination occurs with the condition of decreasing hyperglycemia, glycosuria, depending on the patient's well-being.
Biosulin P is most often injected subcutaneously, less often by intramuscular injection. The absorption and time of the development of the effect depends not only on the mode of administration, but also on the place, amount and concentration of insulin.
Form of issue and composition
Biosulin P is available as a solution for injection with a dosage of 100 units / 1 ml. The vial may contain 5 ml or 10 ml; 1, 2, 3 or 5 pieces in the package. The manufacturer of the drug is Marvel LifeSciences (India).
- Insulin soluble - 100 mg;
- various auxiliary substances.
The medicine belongs to the group of insulin used for substitution treatment, it is produced by genetic engineering method, it is subject to prescription leave.
Indications for use
- insulin-dependent diabetes mellitus (type I);
- insulin-independent type of diabetes mellitus (type II) with the development of resistance to oral hypoglycemic drugs;
- non-insulin-dependent type of diabetes mellitus (type II) with the development of partial resistance to oral hypoglycemic drugs in the appointment of combined treatment;
- intercurrent diseases (acute diseases complicating the course of diabetes mellitus of any type);
- decompensation of carbohydrate metabolism, which is the cause of an emergency in people with diabetes.
In addition, according to the doctor's prescription, insulin can be used in such cases:
- in preparation for surgical manipulation in people with type II diabetes mellitus;
- with diabetes in pregnant women;
- As an anabolic drug in severe exhaustion;
- with furunculosis,
- with hyperthyroidism;
- with atony or ptosis of the stomach;
- with chronic forms of hepatitis;
- with cirrhosis of the liver at the onset of the disease;
- in a state of hypoglycemic coma;
- in the treatment of acute heart failure.
Biosulin P is contraindicated:
- with increased sensitivity to the active substance or other components of the drug;
- hypoglycemic state of any origin;
- with acute hepatic, pancreatic, renal diseases;
- with peptic ulcer of the gastrointestinal tract;
- with heart defects in the stage of decompensation;
- in coronary heart failure.
Mode of application
The medicine is administered 30 minutes before meals. Dosage is selected by the doctor individually.
The average amount per day is 0.5 to 1 IU per kilogram of patient weight.
When using Biosulin P as a mono drug, it is administered 3 times / day or increased to 5-6 times if necessary. If the dose is more than 0.6 IU / kg per day, it should be used in different places in the form of 2 or more injections.
The most frequent place of introduction of Biosulin P is the abdominal wall, but it is possible to apply in the buttock, thigh, and shoulder area. To prevent the development of dystrophy of adipose tissue at the injection site, the injection site must be changed.
Intramuscular and intravenous administration is performed only under the supervision of a physician.
The introduction is made as follows:
- with the help of two fingers a skin fold is formed;
- a needle is inserted into its base at an angle of 45 degrees;
- subcutaneously lead and for a full injection hold a few seconds of the needle under the skin, then remove.
If blood was injected at the injection site, it is necessary to press it with your finger and hold it.
- hypoglycemia, manifested by pallor, increased sweating, tachycardia, tremor, a sensation of crawling along the body, a feeling of hunger. Increased hypoglycemia leads to hypoglycemic coma.
- redness, itching and swelling at the injection site;
- dystrophy of adipose tissue when administered in one place;
- hypersensitivity reactions in the form of rashes, Quincke's edema, it is very rare that anaphylaxis develops;
- edema or visual impairment at the initial stage of therapy.
The reasons for the development of hypoglycemia can be:
- an overdose of a substance;
- replacement of the drug;
- lack of food after the introduction of the drug;
- vomiting, diarrhea;
- increased physical activity;
- diseases in which there is a decrease in the body's need for hormones, such as liver or kidney pathologies, a decrease in the functional activity of the adrenal glands, the pituitary gland or the thyroid gland;
- interaction with other drugs.
- when changing the color of the solution, the appearance of turbidity or particles, further use is contraindicated;
- when treating with insulin preparations, it is necessary to carry out a constant control of the amount of glucose in the blood;
- with prolonged interruptions between administration or application of an incorrect dosage, the development of hyperglycemia, which is manifested by a sensation of thirst, frequent urination, nausea and vomiting, the appearance of redness and dryness of the skin, a decrease in appetite and the smell of acetone from the patient, may be gradually developed. In the absence of therapy of this condition, it is possible to develop ketoacidosis, which is life-threatening;
- with increased physical exertion, infections, fever, thyroid, liver, kidney and other pathologies, as well as over the age of 65 and changing the diet, the dose of the drug should be adjusted;
- some diseases can increase the need for insulin (for example, various infections with fever);
- when a drug is changed, glucose control in the blood is necessary;
- Biosulin P reduces the absorption of alcohol;
- the use of insulin pumps is not recommended because of possible sedimentation of the drug in catheters.
- With various changes associated with insulin therapy, there may be a decrease in the ability to drive or perform work that requires increased attention.
- increase in the sugar-reducing effect of Biosulin P is observed with the intake of: tableted hypoglycemic agents, certain antidepressants, hypolipidemic, hypotensive and diuretic drugs, bromocriptine, octreotide, sulfonamide and tetracycline antibiotics, steroid anabolic agents, ketoconazole, mebendazole, vitamin B6, cyclophosphamide, fenfluramine, based lithium; alcohol-containing drugs.
- decrease in hypoglycemic effect occurs with the use of hormonal contraceptives, glucocorticosteroids, thyroid hormones, certain diuretics and antidepressants, heparin, sympathomimetic drugs, danazol, clonidine, hypotensive drugs, diazoxide, narcotic analgesics, nicotine.
- Reserpine can weaken and enhance the action of Biosulin R.
Biosulin P analogues are short-acting insulins and preparations similar to them:
- Actrapid NM is available in 10 ml vials. Manufacturer: Novo Nordisk (Denmark). Actrapid HM Penfill from the same manufacturer is produced in a 3 ml bottle for a penfill. There are 5 cartridges in the package;
- Vozulim-P also happens in the form of cartridges and bottles, manufactured by Wockhardt Limited (India);
- Gensulin R domestic production company-manufacturer: Bioton Vostok ZAO (Russia);
- Insuman Rapid GT, Aventis Pharma Deutschland GmbH (Germany);
- Insuran R is produced by the Institute of Bioorganic Chemistry. Academicians MM Shemyakin and Yu.A. Ovchinnikov of the Russian Academy of Sciences (Russia);
- Monoinsulin CR, Belmedpreparaty RUE (Republic of Belarus);
- Rinsulin R, GEROFARM-Bio JSC (Russia);
- Rosinsulin R, Medsintez plant (Russia);
- Humulin Regular, Lilly France (France).
Terms and conditions of storage
Shelf life Biosulin R - 2 years. The storage of the drug should be out of reach of children and be protected from sun exposure. The temperature range of storage is 2-8 degrees. The medicine can not be frozen. Application after the expiry date is prohibited.
Biosulin R price
Biosulin P solution for injection 100 units / ml 10 ml - from 450 to 550 rubles.